nad has been researched along with panobinostat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agnihotri, S; Bertrand, KC; Chattopadhyay, A; Golbourn, B; Jane, EP; Mack, SC; Myers, MI; Pollack, IF; Premkumar, DR; Schurdak, ME; Stern, AM; Taylor, DL; Thambireddy, S | 1 |
| Agnihotri, S; Brenner, C; Casillo, SM; Dange, R; Gatesman, TA; Golbourn, BJ; Halbert, ME; Jane, EP; Michealraj, A; Miller, TA; Mohanakrishnan, D; Mullett, SJ; Obodo, U; Pollack, IF; Premkumar, DR; Reslink, MC; Wendell, SG | 1 |
2 other study(ies) available for nad and panobinostat
| Article | Year |
|---|---|
Targeting NAD
Topics: Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Humans; NAD; Panobinostat; Pentosyltransferases; RNA Interference; Sequence Analysis, RNA; Up-Regulation | 2020 |
Targeting mitochondrial energetics reverses panobinostat- and marizomib-induced resistance in pediatric and adult high-grade gliomas.
Topics: Adult; Cell Line, Tumor; Child; Glioma; Humans; Mitochondria; NAD; Panobinostat; Proteasome Inhibitors | 2023 |